If you are navigating menopause, you have likely encountered conflicting advice about hormone therapy. One of the most common and frustrating myths is that there is a strict age limit on when you can start or how long you can stay on hormone therapy. For years, many women have been told they must stop their hormones the day they turn 65, or they have been denied care because they are deemed “too old” to start.
It is time to clear the air with hard clinical evidence. You deserve to make informed, empowered choices about your body, your health, and your quality of life.
Why Consider Hormone Therapy?
For the average woman trying to decide if hormone therapy makes sense, it usually comes down to three main benefits:
- Quality of Life: Severe hot flashes, night sweats, brain fog, and poor sleep can persist for decades in some women. Hormone therapy remains the most effective treatment for these symptoms.
- Bone Health: This is a massive, often under-discussed benefit. After menopause, the drop in estrogen causes rapid bone loss. Hormone therapy is highly effective at preserving bone density and preventing debilitating fractures as we age.
- Vaginal and Urinary Health: Estrogen keeps the tissues of the vagina and urinary tract healthy, preventing painful sex, dryness, and recurrent urinary tract infections.
The “65 and Out” Myth
Let us start with the most persistent rumor: the idea that you must automatically stop hormone therapy at age 65. This rule is outdated and unsupported by current science.
According to the 2022 Position Statement by The Menopause Society (formerly NAMS) and the 2024 International Menopause Society White Paper, there is absolutely no general rule for stopping systemic hormone therapy at age 65. If you are a healthy woman with persistent symptoms or you want to protect your bones, continuing hormone therapy beyond age 65 is a completely reasonable and evidence-based option. The decision belongs in a shared conversation between you and your healthcare provider.
Continuing Therapy: What the Data Shows
Recent studies have provided reassuring data for women who choose to continue their therapy. A large 2024 analysis of Medicare records showed that continuing hormone therapy beyond age 65 was associated with reduced risks for several cardiovascular and mortality outcomes compared to stopping altogether.
The key to long-term safety lies in how you take it. As we age, our baseline risk for blood clots and strokes naturally increases. Transitioning from oral estrogen pills to transdermal estrogen (patches, gels, or sprays) bypasses the liver and minimizes these clotting risks, making it a much safer option for ongoing use.
Starting Hormone Therapy Later in Life: Breaking Down the Risks
What if you are over 60, or more than 10 years past your final menstrual period, and you want to start hormone therapy for the first time? You might have heard that the “window of opportunity” has closed.
Medical guidelines do state that routine initiation of hormone therapy in women over 60 carries a different risk profile than starting in your 50s. Some observational studies (including a recent 2026 cohort study) report higher relative risks for cardiovascular events if hormone therapy is started for the first time after age 65.
However, we need to break those numbers down. While the “relative risk” might look higher in some studies, the “absolute risk” (the actual chance of an event happening to you) is often very small, especially when modern prescribing methods are used. The 2024 Medicare study and current clinical expertise highlight that the risks associated with starting later are significantly mitigated when we use low doses of transdermal estrogen (through the skin) paired with a body-identical progesterone. Transdermal estrogen does not increase clotting factors in the liver the way oral estrogen does.
So, if you are struggling with severe hot flashes or rapid bone loss in your late 60s, a personalized approach is still very possible. If you and your provider decide the benefits to your bones and your daily quality of life outweigh the minimal baseline risks, starting low-dose transdermal therapy is a valid, defensible choice.
Do Not Forget Vaginal Estrogen
While systemic hormone therapy requires careful risk assessment as we age, localized vaginal estrogen plays by entirely different rules. Low-dose vaginal estrogen (creams, tablets, or rings) is incredibly safe, does not carry systemic vascular risks, and can be started at literally any age and continued indefinitely.
Your Health, Your Choice
Growing older does not mean you must surrender your quality of life or accept a one-size-fits-all medical mandate. Whether you are considering continuing your therapy past 65, seeking bone protection, or looking for symptom relief for the first time in your 60s, the decision should be rooted in shared decision-making.
Find a provider who listens, respects your goals, understands absolute versus relative risk, and knows the nuances of modern, transdermal hormone care. Your body is yours, and you have the right to choose.
